Your browser is no longer supported. Please, upgrade your browser.
VTVT vTv Therapeutics Inc. monthly Stock Chart
VTVT [NASD]
vTv Therapeutics Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.10% Shs Outstand30.76M Perf Week-1.36%
Market Cap44.60M Forward P/E- EPS next Y-0.77 Insider Trans- Shs Float5.29M Perf Month-16.18%
Income-9.00M PEG- EPS next Q-0.25 Inst Own56.50% Short Float15.28% Perf Quarter-34.09%
Sales2.30M P/S19.39 EPS this Y38.00% Inst Trans3.00% Short Ratio0.52 Perf Half Y-75.04%
Book/sh-15.34 P/B- EPS next Y30.00% ROA-58.10% Target Price1.67 Perf Year-68.95%
Cash/sh0.21 P/C6.86 EPS next 5Y- ROE11.00% 52W Range0.65 - 8.40 Perf YTD-75.87%
Dividend- P/FCF- EPS past 5Y- ROI34.70% 52W High-82.74% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low123.08% ATR0.12
Employees56 Current Ratio0.40 Sales Q/Q6780.00% Oper. Margin- RSI (14)41.85 Volatility7.33% 8.12%
OptionableNo Debt/Eq- EPS Q/Q30.10% Profit Margin- Rel Volume0.05 Prev Close1.47
ShortableYes LT Debt/Eq- EarningsAug 14 AMC Payout- Avg Volume1.56M Price1.45
Recom3.00 SMA20-5.55% SMA50-13.02% SMA200-66.55% Volume78,264 Change-1.36%
Apr-10-18Downgrade Stifel Buy → Hold $12 → $1
Mar-08-18Initiated ROTH Capital Buy $17
Feb-08-18Initiated Northland Capital Outperform $28
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Jul-02-18 07:25AM  Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities ACCESSWIRE -6.49%
Jun-22-18 09:00AM  vTv Therapeutics to Present a Poster at the American Diabetes Associations 78th Scientific Sessions Business Wire -5.99%
Jun-12-18 04:30PM  vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study Business Wire
08:25AM  Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-08-18 07:30AM  [$$] Ron Perelman Bitten by Biotech Stock Deal Barrons.com
Jun-01-18 08:46AM  vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9% Zacks +5.62%
07:42AM  VTv Therapeutics inks licensing agreement with Chinese biotech firm American City Business Journals
May-31-18 07:33AM  vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTvs PDE4 Inhibitor in China and Other Pacific Rim Territories Business Wire +6.91%
May-30-18 07:25AM  Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks ACCESSWIRE
May-15-18 04:52PM  VTv Therapeutics: 1Q Earnings Snapshot Associated Press -8.99%
04:30PM  vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights Business Wire
May-11-18 08:20AM  Todays Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma ACCESSWIRE -8.37%
May-09-18 04:30PM  vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June Business Wire
Apr-30-18 06:00AM  Key executive leaving High Point biotech firm following disappointing trial results American City Business Journals -8.21%
Apr-18-18 08:20AM  Todays Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics ACCESSWIRE +84.87%
Apr-17-18 05:06PM  vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback American City Business Journals +43.25%
02:43PM  VTv Therapeutics shares surge 40 percent American City Business Journals
Apr-16-18 06:00AM  Cambrex, poised for another expansion, buys two properties for $10.2M American City Business Journals +9.30%
Apr-10-18 10:15AM  vTv Therapeutics Crashes on Alzheimer's Drug Study Failure Zacks -78.09%
09:36AM  Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial Benzinga
02:29AM  Shares of vTv Therapeutics plummet as Alzheimer's study disappoints MarketWatch
Apr-09-18 07:15PM  Vtv Therapeutics price plummets after disappointing trial results American City Business Journals
04:46PM  vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimers Disease Business Wire
Mar-27-18 07:20AM  Wired News vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes ACCESSWIRE
Mar-26-18 07:17AM  UPDATED: vTv Therapeutics reaches milestone in study of its diabetes drug American City Business Journals
Mar-22-18 05:00PM  vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes Business Wire
03:25PM  Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant Benzinga
Feb-28-18 05:04AM  VTv Therapeutics reports 4Q loss Associated Press -8.72%
Feb-27-18 05:15PM  vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Business Wire
Feb-16-18 08:25AM  Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-18 07:31AM  The Triad's best and worst stocks of 2017 (Slideshow) American City Business Journals
Dec-29-17 12:37PM  ETFs with exposure to vTv Therapeutics, Inc. : December 29, 2017 Capital Cube +8.09%
Dec-26-17 07:30AM  Wired News vTv Therapeutics Signs Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical for its GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories ACCESSWIRE
Dec-22-17 12:56PM  Another day, another deal: vTv Therapeutics signs licensing agreement with Reneo American City Business Journals -6.32%
Dec-21-17 04:30PM  vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program Business Wire
03:00AM  vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTvs GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories Business Wire
Dec-20-17 04:14PM  vTv Therapeutics raises $10 million American City Business Journals
Dec-04-17 07:55AM  Market Trends Toward New Normal in Patterson-UTI Energy, SAExploration, vTv Therapeutics, Outfront Media, Mylan N.V, and Axcelis Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-13-17 07:30AM  vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimers Disease Business Wire
Nov-08-17 04:35PM  vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes Business Wire
Nov-06-17 12:42PM  ETFs with exposure to vTv Therapeutics, Inc. : November 6, 2017 Capital Cube
Nov-03-17 10:05AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 08:30AM  Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings Future Expectations, Projections Moving into 2018 GlobeNewswire
05:50AM  VTv Therapeutics reports 3Q loss Associated Press
Nov-01-17 04:30PM  vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results Business Wire
Oct-30-17 07:00AM  vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimers Disease (CTAD) Business Wire
Oct-12-17 08:52AM  Why vTv Therapeutics (VTVT) Could Be Positioned for a Surge Zacks
Oct-11-17 12:11PM  ETFs with exposure to vTv Therapeutics, Inc. : October 11, 2017 Capital Cube +6.06%
Sep-07-17 07:00AM  vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes Business Wire
Sep-06-17 02:56PM  vTv Therapeutics snags funding for study of its diabetes-targeting drug American City Business Journals +6.78%
07:00AM  JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes Business Wire
Aug-31-17 09:59PM  ETFs with exposure to vTv Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-24-17 10:30AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-03-17 08:30AM  vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon Business Wire
05:06AM  VTv Therapeutics reports 2Q loss Associated Press
Aug-02-17 04:30PM  vTv Therapeutics Reports Second Quarter 2017 Financial and Operational Results Business Wire
Jul-20-17 03:08PM  'We're not going to be taken off' vTv Therapeutics CEO responds to NASDAQ's delisting warning American City Business Journals
Jul-13-17 04:30PM  vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference Business Wire
Jun-11-17 04:00PM  vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions Business Wire
Jun-08-17 04:30PM  vTv Therapeutics to Present Two Posters at the American Diabetes Associations 77th Scientific Sessions Business Wire
Jun-01-17 07:00AM  vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimers Disease Business Wire
May-24-17 08:00AM  Corporate insiders have sold $4B in stock in 30 days; here's who's buying and selling in the Triad American City Business Journals
May-22-17 02:18PM  ETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017 Capital Cube
May-05-17 11:11AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube
May-04-17 04:28PM  ETFs with exposure to vTv Therapeutics, Inc. : May 4, 2017 Capital Cube
May-03-17 06:25PM  VTv Therapeutics reports 1Q loss Associated Press
04:30PM  vTv Therapeutics Reports First Quarter 2017 Financial and Operational Results Business Wire
Apr-05-17 05:42PM  ETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017 Capital Cube
Mar-29-17 08:01AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-15-17 10:05AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017 Capital Cube
Mar-10-17 01:30PM  vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences Business Wire
Mar-02-17 01:04PM  VTV THERAPEUTICS INC. Financials
Feb-28-17 04:56PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Feb-27-17 07:32PM  VTv Therapeutics reports 4Q loss Associated Press +7.91%
06:15PM  vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Business Wire
Feb-24-17 09:26AM  VTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report
Jan-25-17 08:40AM  vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher Zacks
Dec-15-16 05:02PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-14-16 04:30PM  vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes Business Wire
Nov-16-16 09:03AM  New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinsons Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego Business Wire
Nov-15-16 04:24PM  Horizon Technology Finance Leads $25 Million Venture Loan Facility for vTv Therapeutics GlobeNewswire +9.88%
07:27AM  Applied Materials (AMAT) Q4 Earnings: Surprise in Store?
Nov-14-16 09:24AM  Can JD.com (JD) Stock Surprise Investors in Q3 Earnings?
08:56AM  Can Agilent Technologies (A) Pull a Surprise in Q4 Earnings? Zacks
Nov-10-16 04:30PM  vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences Business Wire
Nov-07-16 01:08PM  ETFs with exposure to vTv Therapeutics, Inc. : November 7, 2016
Nov-04-16 12:00PM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016
Nov-03-16 04:34PM  VTV THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report
05:08AM  VTv Therapeutics reports 3Q loss
Nov-02-16 04:47PM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -6.52%
04:30PM  vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights Business Wire
Oct-31-16 07:01AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
Oct-24-16 08:30AM  vTv Therapeutics to Present at Peptide Therapeutics Symposium Business Wire
Oct-03-16 07:30AM  vTv Therapeutics to Present at Neuro Advance Boston Business Wire
Sep-26-16 11:46AM  vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
07:14AM  Coverage initiated on vTv Therapeutics by H.C. Wainwright
Sep-08-16 07:00AM  vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference Business Wire
Sep-07-16 07:00AM  vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimers Disease Business Wire
Sep-02-16 07:00AM  vTv Therapeutics to Present at the International Psychogeriatric Association International Congress Business Wire
Aug-17-16 06:05AM  VTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERELMAN RONALD O10% OwnerJul 06Buy4.38570,7762,499,9994,327,994Jul 10 04:55 PM
PERELMAN RONALD O10% OwnerJun 18Buy4.38570,7762,499,9993,757,218Jun 20 04:30 PM
PERELMAN RONALD O10% OwnerMay 24Buy4.38570,7762,499,9993,186,442May 29 04:59 PM
KINDLER JEFFREY BExecutive ChairmanMar 10Option Exercise0.0011,667011,667Mar 12 04:05 PM
PERELMAN RONALD O10% OwnerDec 26Buy4.0350,000201,7202,615,666Dec 27 04:43 PM
SAVAS PAUL GDirectorDec 07Buy4.575,00022,85786,781Dec 07 07:47 PM
SAVAS PAUL GDirectorDec 06Buy4.5510,00045,50081,781Dec 07 07:47 PM
PERELMAN RONALD O10% OwnerAug 22Buy4.5720,00091,3242,565,666Aug 24 05:49 PM
PERELMAN RONALD O10% OwnerAug 16Buy4.9710,00049,6782,545,666Aug 16 06:16 PM
PERELMAN RONALD O10% OwnerAug 15Buy4.8815,00073,2292,535,666Aug 15 06:18 PM
PERELMAN RONALD O10% OwnerAug 14Buy4.6535,000162,7362,520,666Aug 15 06:18 PM
PERELMAN RONALD O10% OwnerAug 11Buy4.4825,000111,9032,485,666Aug 14 04:27 PM
PERELMAN RONALD O10% OwnerAug 10Buy3.9860,000238,9622,460,666Aug 14 04:27 PM